{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:45:24Z","timestamp":1759837524838,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:00:00Z","timestamp":1538179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:00:00Z","timestamp":1538179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-DA021525"],"award-info":[{"award-number":["U01-DA021525"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10461-018-2226-y","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T08:16:25Z","timestamp":1538208985000},"page":"1258-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Engagement in Maximally-Assisted Therapy and Adherence to Antiretroviral Therapy Among a Cohort of Indigenous People Who Use Illicit Drugs"],"prefix":"10.1007","volume":"23","author":[{"given":"Brittany","family":"Barker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kora","family":"DeBeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Shoveller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-6221","authenticated-orcid":false,"given":"M.-J.","family":"Milloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,29]]},"reference":[{"key":"2226_CR1","volume-title":"HIV in British Columbia: Annual Surveillance Report 2012","author":"BC Centre for Disease Control","year":"2013","unstructured":"BC Centre for Disease Control. HIV in British Columbia: Annual Surveillance Report 2012. Canada: Vancouver; 2013."},{"key":"2226_CR2","unstructured":"Public Health Agency of Canada. HIV\/AIDS Epi updates\u2014chapter 1: national HIV prevalence and invidence estimates for 2011. Ottawa, Canada: Government of Canada, 2014. \n                    http:\/\/www.phac-aspc.gc.ca\/aids-sida\/publication\/epi\/2010\/1-eng.php\n                    \n                  . Accessed 15 Nov 2016."},{"issue":"2","key":"2226_CR3","doi-asserted-by":"publisher","first-page":"e87872","DOI":"10.1371\/journal.pone.0087872","volume":"9","author":"JSG Montaner","year":"2014","unstructured":"Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV\/AIDS morbidity, mortality and HIV transmission: The \u201cHIV treatment as prevention\u201d experience in a Canadian setting. PLoS ONE. 2014;9(2):e87872.","journal-title":"PLoS ONE"},{"key":"2226_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(10)60832-X","volume":"376","author":"D Wolfe","year":"2010","unstructured":"Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376:355\u201366.","journal-title":"Lancet"},{"key":"2226_CR5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF03404154","volume":"102","author":"LJ Martin","year":"2011","unstructured":"Martin LJ, Houston S, Yasui Y, et al. All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use. Can J Public Health. 2011;102:90\u20136.","journal-title":"Can J Public Health"},{"key":"2226_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/157016210794088227","volume":"8","author":"LJ Martin","year":"2010","unstructured":"Martin LJ, Houston S, Yasui Y, et al. Rates of initial virological suppression and subsequent virological failure after initiating Highly active antiretroviral therapy: the impact of aboriginal ethnicity and injection drug use. Curr HIV Res. 2010;8:649\u201358.","journal-title":"Curr HIV Res"},{"key":"2226_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.284.2.179","volume":"284","author":"PB Fontanarosa","year":"2000","unstructured":"Fontanarosa PB, Babudieri S, Aceti A, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179\u201380.","journal-title":"JAMA"},{"key":"2226_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2105\/AJPH.2005.083253","volume":"97","author":"P Myung","year":"2007","unstructured":"Myung P, Pugatch D, Brady MF, et al. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia. Am J Public Health. 2007;97:974\u20137.","journal-title":"Am J Public Health"},{"key":"2226_CR9","first-page":"545","volume":"39","author":"JA Mitty","year":"2005","unstructured":"Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. JAIDS. 2005;39:545\u201350.","journal-title":"JAIDS"},{"key":"2226_CR10","unstructured":"Community AIDS Treatment Information Exchange (CATIE). Maximally assisted therapy (MAT) program. Toronto, Canada: CATIE, 2013. \n                    http:\/\/www.catie.ca\/en\/pc\/program\/mat-program\n                    \n                  . Accessed 2 Dec 2016."},{"key":"2226_CR11","unstructured":"Vancouver Native Health Society. Positive outlook program. In. Vancouver, Canada: Vancouver Native Health Society; 2016. \n                    http:\/\/www.vnhs.net\/programs-services\/positive-outlook-program\n                    \n                  . Accessed 23 April 2018."},{"key":"2226_CR12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s10461-011-0026-8","volume":"15","author":"S Parashar","year":"2011","unstructured":"Parashar S, Palmer AK, O\u2019Brien N, et al. Sticking to it: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed. AIDS Behav. 2011;15:1612\u201322.","journal-title":"AIDS Behav"},{"key":"2226_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.drugpo.2006.11.009","volume":"18","author":"MW Tyndall","year":"2007","unstructured":"Tyndall MW, McNally M, Lai C, et al. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy. 2007;18:281\u20137.","journal-title":"Int J Drug Policy"},{"issue":"Suppl 1","key":"2226_CR14","first-page":"S96","volume":"43","author":"ML Petersen","year":"2006","unstructured":"Petersen ML, Wang Y, van der Laan MJ, et al. Assessing the effectiveness of antiretroviral adherence interventions: using marginal structural models to replicate the findings of randomized controlled trials. JAIDS. 2006;43(Suppl 1):S96\u2013103.","journal-title":"JAIDS"},{"key":"2226_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1086\/521250","volume":"45","author":"ML Petersen","year":"2007","unstructured":"Petersen ML, Wang Y, van der Laan MJ, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007;45:908\u201315.","journal-title":"Clin Infect Dis"},{"key":"2226_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.280.6.547","volume":"280","author":"B Yip","year":"1998","unstructured":"Yip B, Palepu A, Montaner JSG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547\u20139.","journal-title":"JAMA"},{"key":"2226_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jama.300.5.550","volume":"300","author":"E Wood","year":"2008","unstructured":"Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550.","journal-title":"JAMA"},{"key":"2226_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7448\/IAS.19.1.20617","volume":"19","author":"MJ Milloy","year":"2016","unstructured":"Milloy MJ, King A, Kerr T, et al. Improvements in HIV treatment outcomes among Indigenous and non-indigenous people who use illicit drugs in a Canadian setting. J Int AIDS Soc. 2016;19:1\u20138.","journal-title":"J Int AIDS Soc"},{"key":"2226_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1080\/09540121.2010.543882","volume":"23","author":"S Nolan","year":"2011","unstructured":"Nolan S, Milloy MJ, Zhang R, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care. 2011;23:980\u20137.","journal-title":"AIDS Care"},{"key":"2226_CR20","first-page":"360","volume":"23","author":"S Low-Beer","year":"2000","unstructured":"Low-Beer S, Yip B, O\u2019Shaughnessy MV, et al. Adherence to triple therapy and viral load response. JAIDS. 2000;23:360\u20131.","journal-title":"JAIDS"},{"key":"2226_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","volume":"139","author":"E Wood","year":"2003","unstructured":"Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 \u00d7 109 cells\/L. Ann Intern Med. 2003;139:810\u20136.","journal-title":"Ann Intern Med"},{"key":"2226_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1086\/507680","volume":"194","author":"R Gross","year":"2006","unstructured":"Gross R, Yip B, Re VL III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108\u201314.","journal-title":"J Infect Dis"},{"key":"2226_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/sim.1144","volume":"21","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002;21:1689\u2013709.","journal-title":"Stat Med"},{"key":"2226_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n M\u00c1, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550\u201360.","journal-title":"Epidemiology"},{"issue":"615\u2013625","key":"2226_CR25","first-page":"26","volume":"15","author":"MA Hern\u00e1n","year":"2004","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(615\u2013625):26.","journal-title":"Epidemiology"},{"issue":"5","key":"2226_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/cid\/civ929","volume":"62","author":"M-J Milloy","year":"2016","unstructured":"Milloy M-J, Wood E, Kerr T, Hogg B, Guillemi S, Harrigan PR, et al. Increased prevalence of controlled viremia and decreased rates of HIV drug resistance among HIV-positive people who use illicit drugs during a community-wide treatment-as-prevention initiative. Clin Infect Dis. 2016;62(5):640\u20137.","journal-title":"Clin Infect Dis"},{"key":"2226_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/09540121.2015.1035634","volume":"27","author":"A Erickson","year":"2015","unstructured":"Erickson A, Becker M, Shaw S, et al. Substance use and its impact on care outcomes among HIV-infected individuals in Manitoba. AIDS Care. 2015;27:1168\u201373.","journal-title":"AIDS Care"},{"key":"2226_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/15381501.2011.623903","volume":"10","author":"T Prentice","year":"2011","unstructured":"Prentice T, Mill J, Archibald CP, et al. Aboriginal youth experiences of accessing HIV care and treatment. J HIV\/AIDS Soc Serv. 2011;10:395\u2013413.","journal-title":"J HIV\/AIDS Soc Serv"},{"key":"2226_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1177\/1049732309353907","volume":"19","author":"J McCall","year":"2009","unstructured":"McCall J, Browne AJ, Reimer-Kirkham S. Struggling to survive: the difficult reality of Aboriginal women living with HIV\/AIDS. Qual Health Res. 2009;19:1769\u201382.","journal-title":"Qual Health Res"},{"key":"2226_CR30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF03403708","volume":"98","author":"J Larkin","year":"2007","unstructured":"Larkin J, Flicker S, Koleszar-Green R, et al. HIV risk, systemic inequities, and Aboriginal youth: widening the circle for HIV prevention programming. Can J Public Health. 2007;98:179\u201382.","journal-title":"Can J Public Health"},{"key":"2226_CR31","doi-asserted-by":"crossref","unstructured":"Matthews R. The cultural erosion of Indigenous people in health care. Can Med Assoc J 2016: published ahead of print.","DOI":"10.1503\/cmaj.160167"},{"key":"2226_CR32","first-page":"e120","volume":"5","author":"SB Rourke","year":"2011","unstructured":"Rourke SB, Sobota M, Tucker R, et al. Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the positive spaces, healthy places study. Open Med. 2011;5:e120.","journal-title":"Open Med"},{"key":"2226_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.drugpo.2007.07.005","volume":"19","author":"A Mehrabadi","year":"2008","unstructured":"Mehrabadi A, Craib KJP, Patterson K, et al. The cedar project: a comparison of HIV-related vulnerabilities amongst young Aboriginal women surviving drug use and sex work in two Canadian cities. Int J Drug Policy. 2008;19:159\u201368.","journal-title":"Int J Drug Policy"},{"key":"2226_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3402\/ijch.v66i3.18259","volume":"66","author":"PM Spittal","year":"2007","unstructured":"Spittal PM, Craib KJP, Teegee M, et al. The cedar project: prevalence and correlates of HIV infection among young Aboriginal people who use drugs in two Canadian cities. Int J Circumpolar Health. 2007;66:226\u201340.","journal-title":"Int J Circumpolar Health"},{"key":"2226_CR35","first-page":"e220","volume":"3","author":"KJ Craib","year":"2009","unstructured":"Craib KJ, Spittal PM, Patel SH, et al. Prevalence and incidence of hepatitis C virus infection among Aboriginal young people who use drugs: results from the cedar project. Open Med. 2009;3:e220.","journal-title":"Open Med"},{"key":"2226_CR36","unstructured":"Public Health Agency of Canada. Population-specific HIV\/AIDS status report: Aboriginal peoples. Ottawa, Canada: Government of Canada, 2010. \n                    http:\/\/www.phac-aspc.gc.ca\/aids-sida\/publication\/ps-pd\/index-eng.php\n                    \n                  . Accessed 4 Nov 2016."},{"key":"2226_CR37","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1086\/503905","volume":"42","author":"GM Lucas","year":"2006","unstructured":"Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628\u201335.","journal-title":"Clin Infect Dis"},{"key":"2226_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jinf.2005.07.008","volume":"52","author":"E Wood","year":"2006","unstructured":"Wood E, Kerr T, Palepu A, et al. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. J Infect. 2006;52:233\u20136.","journal-title":"J Infect"},{"key":"2226_CR39","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1086\/378703","volume":"188","author":"E Wood","year":"2003","unstructured":"Wood E, Montaner JSG, Tyndall MW, et al. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis. 2003;188:1164\u201370.","journal-title":"J Infect Dis"},{"key":"2226_CR40","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1503\/cmaj.109-5105","volume":"187","author":"L Vogel","year":"2015","unstructured":"Vogel L. HIV in Saskatchewan merits urgent response. Can Med Assoc J. 2015;187:793\u20134.","journal-title":"Can Med Assoc J"},{"key":"2226_CR41","unstructured":"British Columbia Ministry of Aboriginal Relations and Reconcilliation. Government standard for aboriginal administrative data. Victoria, Canada: Government of British Columbia, 2007. \n                    http:\/\/www2.gov.bc.ca\/assets\/gov\/government\/services-for-government-and-broader-public-sector\/information-technology-services\/standards-files\/aboriginal_administrative_data_standards.pdf\n                    \n                  . Accessed 6 May 2016."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-018-2226-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10461-018-2226-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-018-2226-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T12:28:31Z","timestamp":1589718511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10461-018-2226-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,29]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1007\/s10461-018-2226-y","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"type":"print","value":"1090-7165"},{"type":"electronic","value":"1573-3254"}],"subject":[],"published":{"date-parts":[[2018,9,29]]},"assertion":[{"value":"29 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Milloy is supported in part by the US National Institutes of Health (U01-DA021525), a Scholar award from the Michael Smith Foundation for Health Research (MSFHR), and a New Investigator award from the Canadian Institutes of Health Research. Dr. Milloy and his institution have received an unstructured gift from NG Biomed, Ltd., a private firm seeking a license from the Canadian government to produce medical cannabis, to support him. This work was supported in part by a Tier 1 Canada Research Chair in Inner-City Medicine awarded to Dr. Wood. Dr. Montaner is supported by the British Columbia Ministry of Health and through an Avant-Garde Award (No. 1DP1DA026182) from the National Institute of Drug Abuse (NIDA), at the US National Institutes of Health (NIH). He has also received financial support from the International AIDS Society, United Nations AIDS Program, World Health Organization, NIH Office of AIDS Research, National Institute of Allergy and Infectious Diseases, The United States President\u2019s Emergency Plan for AIDS Relief (PEPfAR), UNICEF, the University of British Columbia, Simon Fraser University, Providence Health Care and Vancouver Coastal Health Authority. Dr. Kora DeBeck is supported by a MSFHR\/St. Paul\u2019s Hospital Foundation-Providence Health Care Career Scholar Award and a Canadian Institutes of Health Research New Investigator Award. Brittany Barker is supported by a Canadian Institutes of Health Research Doctoral Award. The funders had no role in the design and conduct of this study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of British Columbia and Providence Health Care research ethics board, the Tri-Council policy statement for research involving human participants, as well as the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}